Shots: The termination of 2014 deal, is based on evaluation of portfolio and prioritization of assets within Janssen’s portfolio Janssen to support Geron involving transfer of ongoing clinical trials, regulatory, […]readmore
Tags : Agreement
Shots: Novartis to get royalty-free worldwide, intellectual property rights for CBMG’s CAR-T related technology. CBMG to get a mark-up on the manufacturing cost. CBMG will take care of the manufacturing […]readmore
Shots: Moberg to receive $14.6M as upfront and milestone payments of $4.6M for development and regulatory ($0.5M initial payment) and $10M on commercialization of product Moberg will be responsible for […]readmore
Shots: Pfizer will pay access fee for using Atomwise’s AI technology with success-based payments for each target protein selected, while Atomwise will computationally analyse various small molecules for each of […]readmore
Shots: The agreement involves assessing safety, efficacy and tolerability of BeiGene’s RAFi dimer, lifirafenib (BGB-283) and SpringWorks’ MEKi (PD-0325901), in patients with advanced solid tumours BeiGene will look forward for […]readmore
Shots: Pfizer signed a Co-promotion agreement for Exact Sciences Cologuard,first and only FDA-approved non-invasive stool DNA screening test for colorectal cancer(CRC) Pfizer will co-promote Cologuard with Exact from Q4’18, also […]readmore
Shots: With this collaboration GSK plans improve target selection to develop “Precision Medicine” with better efficacy and safety To identify specific subgroups population to develop targeted treatments GSK is initially […]readmore